Drug Pricing Tomorrow: FPMAJ’s Kamoya Says Innovation Premium Meant to Head Off Future Drug Lags

Yoshiaki Kamoya, Chairman, FPMAJ NHI Drug Pricing Study Committee The true goal of the price maintenance premium for on-patent medicines is to prevent future drug lags by allowing companies to recoup past investments faster, says Yoshiaki Kamoya, chairman of the...read more